Senseonics Q2 2026 Earnings: Revenue Doubles but Expenses Widen Loss

Senseonics (NASDAQ: SENS) reported Q2 2026 revenue of $14.5 million, up approximately 120% from $6.6 million a year earlier, while diluted net loss per share widened to $0.63 from $0.36. Gross margin expanded by about 12 percentage points, but higher commercial integration and product-development expenses increased the net loss to $36.7 million. The company also raised its full-year revenue and gross margin guidance.

Core Financial Results

For the quarter ended June 30, 2026, revenue growth and a higher gross margin lifted gross profit to $8.6 million. However, the increase in operating expenses was substantially larger than the gross profit improvement.

Selling, general and administrative expense rose primarily because Senseonics brought commercial operations in-house and completed its European transition. Research and development spending increased as the company advanced the Gemini clinical program and continued developing Freedom.

Business and Regional Performance

The U.S. business generated $12.6 million of revenue, up more than 150% from $4.9 million. Senseonics reported its highest quarterly shipment volume, while the number of active prescribers increased approximately 130% year over year. Management said direct-to-consumer activity had become the largest source of new patients, alongside improved productivity in the healthcare provider channel.

Revenue outside the U.S. increased approximately 12% to $1.9 million from $1.7 million. The slower international growth reflected the timing of European tender updates while Senseonics transitioned commercial operations from Ascensia. The company completed that transition in June and now directly controls sales and marketing operations in Germany, Italy, Spain and Sweden.

Eon Care expanded to more than 90 nurses and handled approximately 40% of Eversense insertion procedures. Senseonics maintained its goal of reaching 100 nurses by year-end. Management also reported continued uptake of Eversense 365 with the twiist automated insulin delivery system, although it did not provide a quantitative adoption figure.

Revenue Growth and Margin Gains Did Not Offset Expense Expansion

The quarter’s central financial tension was the gap between improving product economics and rapidly rising operating costs. Gross profit increased by about $5.4 million, but combined R&D and SG&A expenses rose by approximately $27.1 million, producing a substantially larger operating loss.

The spending increase reflects two distinct initiatives. Commercial integration, including the European transition, drove SG&A higher, while Gemini clinical work and Freedom development increased R&D expense. These investments supported the company’s commercialization and product pipeline, but their near-term cost more than absorbed the benefits of higher revenue and gross margin.

Balance Sheet and Liquidity

At June 30, 2026, Senseonics held $44.8 million of cash and cash equivalents, $0.3 million of restricted cash and $97.9 million of short-term investments. Together, these balances totaled approximately $143.0 million.

The company raised more than $100 million during the quarter, including approximately $90 million of equity proceeds, and expanded its Hercules Capital facility to as much as $140 million. Long-term debt and notes payable, net, increased to $55.8 million from $35.6 million at December 31, 2025. Inventory also rose to $8.5 million from $6.7 million over the same period.

Full-Year 2026 Guidance

Senseonics raised both ends of its revenue forecast by $2 million and increased both ends of its gross margin range by three percentage points. The revised outlook assumes continued international rollout of Eversense 365, planned direct-to-consumer marketing, execution of other commercial initiatives and ongoing use of patient assistance programs.

Europe is still expected to contribute approximately 20% of full-year revenue, with management anticipating that tender-related timing effects will normalize during the third and fourth quarters.

Recent Insider Transactions

The supplied insider data showed no open-market purchases or sales during the most recent six-month period. The latest 10 reported transactions were direct stock awards to directors, so they should not be interpreted as discretionary buying or selling.

Risks Investors Should Watch

• Operating expenses remain well above gross profit. Continued spending on commercial integration, Gemini and Freedom could keep losses elevated even if revenue and gross margin improve.
• European growth depends partly on tender timing. International revenue increased only 12% during the quarter, and the full-year outlook assumes that European timing effects normalize in the second half.
• Commercial scaling remains an execution requirement. Guidance depends on direct-to-consumer marketing, healthcare provider productivity, Eon Care expansion and patient assistance program utilization.
• The company remains dependent on external capital while reporting substantial losses. Senseonics strengthened its balance sheet through equity financing and an expanded credit facility, but debt increased and access to future Hercules borrowings remains subject to applicable conditions.

Summary

Senseonics delivered rapid U.S.-led revenue growth and a meaningful gross margin expansion in Q2 2026, prompting higher full-year revenue and margin guidance. The main offset was a sharp increase in commercial and development expenses, which widened the operating and net losses. The next areas to monitor are whether European revenue normalizes, whether Eon Care and U.S. commercialization continue scaling, and whether gross profit growth begins to narrow the gap with operating spending.